Sen. Grassley Receives FDA Update on Investigation Into Unproven Treatments
June 17, 2019
June 17, 2019
WASHINGTON, June 17 -- Sen. Chuck Grassley, R-Iowa, chairman of the Senate Finance Committee, issued the following news:
Sen. Chuck Grassley (R-Iowa) received a letter (https://www.finance.senate.gov/imo/media/doc/2019-2319%20RESPONSE.pdf) from the U.S. Food and Drug Administration (FDA) in response to his April 13, 2018 letter (https://www.grassley.senate.gov/sites/default/files/constituents/upload/2018-04-13%20CEG%20to%20HHS%20and%20FDA%20(Stem%20Cell%20Trial).pdf) to Department o . . .
Sen. Chuck Grassley (R-Iowa) received a letter (https://www.finance.senate.gov/imo/media/doc/2019-2319%20RESPONSE.pdf) from the U.S. Food and Drug Administration (FDA) in response to his April 13, 2018 letter (https://www.grassley.senate.gov/sites/default/files/constituents/upload/2018-04-13%20CEG%20to%20HHS%20and%20FDA%20(Stem%20Cell%20Trial).pdf) to Department o . . .